Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Total Therapy for Adult T-ALL/LBL
NCT03564704Phase 3Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Feb 2016
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tucidinostat in T-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Event-Free-Survival at 3 years. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
T-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT03564704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564704.